Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1500-pRCC,Adv, Sunitinib vs MET inhib | 1 | Y | 1 Sunitinib | 180 | 20 | 11 | 6 | 2 | 1 | 0 | 07/25/2016 | 225 | 96 |
| 2 Cabozantinib | 18 | 10 | 6 | 3 | 0 | 0 | ||||||||
| 3 Crizotinib | 21 | 13 | 8 | 4 | 2 | 2 | ||||||||
| 4 Savolitinib | 20 | 11 | 7 | 3 | 1 | 1 | ||||||||
| 79 | 45 | 27 | 12 | 4 | 3 | |||||||||
| S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 1 | Y | 1 TICE BCG | 969 | 32 | 29 | 17 | 9 | 3 | 0 | 02/24/2017 | 148 | 63 | |
| 2 Tokyo-172 BCG | 31 | 29 | 17 | 10 | 5 | 1 | ||||||||
| 3 Prime + Tokyo-172 BCG | 29 | 28 | 15 | 8 | 3 | 0 | ||||||||
| 92 | 86 | 49 | 27 | 11 | 1 | |||||||||
| S1605-Blad, BCG-Unresponsive NMIBC, Atezolizumab | 1 | Y | 1 Atezolizumab | 148 | 41 | 39 | 25 | 10 | 2 | 1 | 03/13/2017 | 159 | 71 | |
| 41 | 39 | 25 | 10 | 2 | 1 | |||||||||
| Yes | A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 1 | E | Total Registrations | 3 | 1 | 1 | 1 | 0 | 0 | 11/23/2016 | 60 | 33 | |
| 3 | 1 | 1 | 1 | 0 | 0 | |||||||||
| EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) | 0 | E | Total Registrations | 15 | 15 | 12 | 8 | 3 | 1 | 09/29/2017 | 38 | |||
| 15 | 15 | 12 | 8 | 3 | 1 | |||||||||
| 1 | E | Total Registrations | 11 | 11 | 8 | 5 | 1 | 0 | 09/29/2017 | |||||
| 11 | 11 | 8 | 5 | 1 | 0 | |||||||||
| NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel | 1 | E | Total Registrations | 1 | 1 | 0 | 0 | 0 | 0 | 08/24/2017 | 123 | |||
| 1 | 1 | 0 | 0 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 1 | 0 | 0 | 0 | 0 | 08/24/2017 | |||||
| 1 | 1 | 0 | 0 | 0 | 0 | |||||||||
| No | R0924-Pros, NADT+WPRT vs. NADT+P&SV RT | 1 | E | Total Registrations | 72 | 30 | 16 | 8 | 0 | 0 | 11/25/2013 | 176 | ||
| 72 | 30 | 16 | 8 | 0 | 0 | |||||||||